CM
AGIO icon

Capula Management’s Agios Pharmaceuticals AGIO Stock Holding History

Capula Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,749
Closed -$872K – 638
2025
Q1 		$872K Buy
29,749
+8,900
+43% +$295K ﹤0.01% 253
2024
Q4 		$685K Buy
+20,849
New +$979K ﹤0.01% 156
2023
Q3 		– Sell
-24,380
Closed -$690K – 506
2023
Q2 		$690K Buy
24,380
+4,060
+20% +$101K 0.02% 211
2023
Q1 		$467K Sell
20,320
-12,700
-38% -$337K 0.01% 470
2022
Q4 		$927K Buy
+33,020
New +$931K 0.01% 458

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capula Management's AGIO Position: Q2 2025 in Review

Capula Management sold out of Agios Pharmaceuticals (AGIO) in Q2 2025, closing a stake of 29,749 shares — an estimated $872K sold.

Capula Management first reported a position in AGIO in Q4 2022 and held it in 5 quarters. The position peaked at $927K in Q4 2022. 214 funds tracked by Wall St. Rank hold AGIO as of Q2 2025.

  • Capula Management reported no remaining Agios Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Capula Management sold 29,749 Agios Pharmaceuticals shares in Q2 2025, an estimated $872K.
  • Capula Management first reported a position in Agios Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Capula Management's Agios Pharmaceuticals position peaked at $927K in Q4 2022.
  • 214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2025.

Based on Capula Management's 13F filing for Q2 2025, filed 13 Aug 2025.